

III. AMENDMENTS TO THE CLAIMS

Claims 1-24. (canceled)

Claim 25. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean fasting plasma concentration vs. time curve of Figure
14 upon single administration to human subjects.

Claim 26. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean fed plasma concentration vs. time curve of Figure
14 upon single administration to human subjects.

Claim 27. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean fasting plasma concentration vs. time curve of Figure
15 upon single administration to human subjects.

Claim 28. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean fed plasma concentration vs. time curve of Figure
15 upon single administration to human subjects.

Claim 29. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean plasma concentration vs. time curve of Figure
16 upon steady state administration to human subjects.

Claim 30. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean fasting plasma concentration vs. time curve of Figure
17 upon single administration to human subjects.

Claim 31. (new) A sustained release oral dosage form comprising:
hydromorphone or a pharmaceutically acceptable salt thereof; and
means for providing the mean fed plasma concentration vs. time curve of Figure
17 upon single administration to human subjects.